Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment

Sangnier, Anouchka Plan; Aufaure, Romain; Motte, Laurence; Wilhelm, Claire; Guénin, Erwann; Lalatonne, Yoann

doi:10.3762/bjnano.9.273

Cited by 12 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Silver-gold hollow nano shells with mesoporous silica nanoparticle have been utilized for the PDT in the experimental PC cells [158]. In another study, a hybrid nanoparticles of Au-alendronate were made for combined PDT-chemotherapy of PC [159]. The PDT not only enhanced the impact of chemotherapy in suppressing PC, but also decreased the dose of the chemotherapy needed for the treatment of PC [160][161][162].…”

Section: Phototherapymentioning

confidence: 99%

Recent advances and future perspectives in the therapeutics of prostate cancer

Varaprasad,

Gupta,

Prasad

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic defects are major factors that determine the aggressiveness and lethality of PC. The African population is at the highest risk of developing high-grade PC. It can be challenging to distinguish between low-risk and high-risk patients due to the slow progression of PC. Prostate-specific antigen (PSA) is a revolutionary discovery for the identification of PC. However, it has led to an increase in over diagnosis and over treatment of PC in the past few decades. Even if modifications are made to the standard PSA testing, the specificity has not been found to be significant. Our understanding of PC genetics and proteomics has improved due to advances in different fields. New serum, urine, and tissue biomarkers, such as PC antigen 3 (PCA3), have led to various new diagnostic tests, such as the prostate health index, 4K score, and PCA3. These tests significantly reduce the number of unnecessary and repeat biopsies performed. Chemotherapy, radiotherapy, and prostatectomy are standard treatment options. However, newer novel hormone therapy drugs with a better response have been identified. Androgen deprivation and hormonal therapy are evolving as new and better options for managing hormone-sensitive and castration-resistant PC. This review aimed to highlight and discuss epidemiology, various risk factors, and developments in PC diagnosis and treatment regimens.

show abstract

Section: Phototherapymentioning

confidence: 99%

Recent advances and future perspectives in the therapeutics of prostate cancer

Varaprasad,

Gupta,

Prasad

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…Furthermore, the tunable size and shape of GNPs is related to a higher photothermal conversion efficiency [162,164]. Finally, the easy surface functionalization of GNPs allows their use as dual photothermal and chemotherapeutical agents [165], which in consequence, leads to a more efficient reduction of the tumor mass. In this regard, it has been reported that GNP-mediated PTT sensitizes tumor cells to other drugs [162], thus reducing their necessary dose or even overcoming drug resistance.…”

Section: Gold As a Vehicle: Biomedical Potential Of Gold Nanopartimentioning

confidence: 99%

Gold as a Possible Alternative to Platinum-Based Chemotherapy for Colon Cancer Treatment

Mármol

Medina-Quero

Rodríguez-Yoldi

et al. 2019

Cancers

View full text Add to dashboard Cite

Due to the increasing incidence and high mortality associated with colorectal cancer (CRC), novel therapeutic strategies are urgently needed. Classic chemotherapy against CRC is based on oxaliplatin and other cisplatin analogues; however, platinum-based therapy lacks selectivity to cancer cells and leads to deleterious side effects. In addition, tumor resistance to oxaliplatin is related to chemotherapy failure. Gold(I) derivatives are a promising alternative to platinum complexes, since instead of interacting with DNA, they target proteins overexpressed on tumor cells, thus leading to less side effects than, but a comparable antitumor effect to, platinum derivatives. Moreover, given the huge potential of gold nanoparticles, the role of gold in CRC chemotherapy is not limited to gold(I) complexes. Gold nanoparticles have been found to be able to overcome multidrug resistance along with reduced side effects due to a more efficient uptake of classic drugs. Moreover, the use of gold nanoparticles has enhanced the effect of traditional therapies such as radiotherapy, photothermal therapy, or photodynamic therapy, and has displayed a potential role in diagnosis as a consequence of their optic properties. Herein, we have reviewed the most recent advances in the use of gold(I) derivatives and gold nanoparticles in CRC therapy.

show abstract

“…In vitro hyperthermia tests showed efficiency in inoculating mouse breast cancer cells. Another study reports the use of alendronate-coated gold nanoparticles [34]. The resulting gold-alendronate nanoplatform combines antitumor activity through drug delivery and photothermal therapy, as illustrated in vitro on the inhibition of prostate cancer cells.…”

Section: Healthmentioning

confidence: 99%